CN107064400A - 同时检测血清中五种类固醇激素的方法 - Google Patents
同时检测血清中五种类固醇激素的方法 Download PDFInfo
- Publication number
- CN107064400A CN107064400A CN201710262704.XA CN201710262704A CN107064400A CN 107064400 A CN107064400 A CN 107064400A CN 201710262704 A CN201710262704 A CN 201710262704A CN 107064400 A CN107064400 A CN 107064400A
- Authority
- CN
- China
- Prior art keywords
- ion
- mobile phase
- matter
- phases
- cortisol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 210000002966 serum Anatomy 0.000 title claims abstract description 35
- 229940088597 hormone Drugs 0.000 title claims abstract description 31
- 239000005556 hormone Substances 0.000 title claims abstract description 31
- 150000003431 steroids Chemical class 0.000 title claims abstract description 25
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 102
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 91
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 55
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 238000001514 detection method Methods 0.000 claims abstract description 48
- 229960003604 testosterone Drugs 0.000 claims abstract description 48
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 39
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 39
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960004544 cortisone Drugs 0.000 claims abstract description 39
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960005471 androstenedione Drugs 0.000 claims abstract description 37
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims abstract description 32
- 238000012360 testing method Methods 0.000 claims abstract description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 11
- 239000006228 supernatant Substances 0.000 claims abstract description 8
- 238000002203 pretreatment Methods 0.000 claims abstract description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000004780 2D liquid chromatography Methods 0.000 claims abstract description 5
- 238000001556 precipitation Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 150000002500 ions Chemical class 0.000 claims description 102
- 240000002853 Nelumbo nucifera Species 0.000 claims description 38
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 38
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 38
- WHBHBVVOGNECLV-UHFFFAOYSA-N 11-deoxy-17-hydroxy-corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 WHBHBVVOGNECLV-UHFFFAOYSA-N 0.000 claims description 28
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- -1 Testosterone ion Chemical class 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 5
- 238000001819 mass spectrum Methods 0.000 claims description 4
- 239000002699 waste material Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 3
- 239000005695 Ammonium acetate Substances 0.000 claims description 3
- 235000019257 ammonium acetate Nutrition 0.000 claims description 3
- 229940043376 ammonium acetate Drugs 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- AEMFNILZOJDQLW-OIBFCKKCSA-N [13CH3][C@@]12C(=O)CC[C@H]1[C@@H]1CCC3=CC(=O)CC[C@]3(C)[C@H]1CC2 Chemical compound [13CH3][C@@]12C(=O)CC[C@H]1[C@@H]1CCC3=CC(=O)CC[C@]3(C)[C@H]1CC2 AEMFNILZOJDQLW-OIBFCKKCSA-N 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 11
- 230000004907 flux Effects 0.000 abstract description 4
- 150000000241 11-deoxycortisols Chemical class 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 58
- 238000011084 recovery Methods 0.000 description 22
- 210000004100 adrenal gland Anatomy 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003270 steroid hormone Substances 0.000 description 3
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000002395 mineralocorticoid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- 206010000002 11-beta-hydroxylase deficiency Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001389 Adrenocortical insufficiency acute Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- KLYCPFXDDDMZNQ-UHFFFAOYSA-N Benzyne Chemical compound C1=CC#CC=C1 KLYCPFXDDDMZNQ-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101600111816 Homo sapiens Sex hormone-binding globulin (isoform 1) Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033264 Ovarian hyperfunction Diseases 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 102300044179 Sex hormone-binding globulin isoform 1 Human genes 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000010981 acute adrenal insufficiency Diseases 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- NXQOQNROJJFYCJ-FZFXZXLVSA-N androst-16-ene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C=CC4)[C@@H]4[C@@H]3CCC21 NXQOQNROJJFYCJ-FZFXZXLVSA-N 0.000 description 1
- 150000001443 androstenes Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 201000006564 estrogen excess Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000001172 liquid--solid extraction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002483 sella turcica Anatomy 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000001154 skull base Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010846 tandem mass spectrometry analysis Methods 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/08—Preparation using an enricher
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N30/14—Preparation by elimination of some components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
相对丰度(K) | K≥50% | 20%≤K≤50% | 10%≤K≤20% | K≤10% |
最大允许误差 | ±20% | ±25% | ±30% | ±50% |
理论浓度(ng/L) | 检测平均值(ng/L) | RSD | 回收率 |
0 | 0 | — | — |
1.2375 | 2.03 | 25% | 164.04% |
2.75 | 2.72 | 3.59% | 99.03% |
5.5 | 5.42 | 4.07% | 98.52% |
11 | 10.92 | 4.27% | 99.24% |
22 | 21.37 | 3.01% | 97.12% |
44.1 | 42.40 | 2.62% | 96.15% |
88.1 | 84.60 | 4.63% | 96.03% |
156 | 154.50 | 2.04% | 99.04% |
313 | 313.83 | 2.36% | 100.27% |
625 | 632.33 | 1.29% | 101.17% |
1250 | 1238.33 | 1.19% | 99.07% |
2500 | 2506.67 | 1.74% | 100.27% |
5000 | 5030.00 | 1.56% | 100.60% |
10000 | 9960.00 | 1.91% | 99.60% |
理论浓度(ng/L) | 检测平均值(ng/L) | RSD | 回收率 |
0 | 0 | — | — |
1.375 | 1.719 | 20.06% | 125.1% |
2.75 | 2.77 | 5.77% | 100.67% |
5.5 | 5.35 | 3.45% | 97.21% |
11 | 11.05 | 5.45% | 100.45% |
22 | 21.03 | 5.10% | 95.61% |
44.1 | 41.17 | 7.09% | 93.35% |
88.1 | 84.87 | 3.66% | 96.33% |
156 | 159.00 | 3.98% | 101.92% |
313 | 325.33 | 3.89% | 103.94% |
625 | 641.33 | 3.24% | 102.61% |
1250 | 1278.33 | 2.64% | 102.27% |
2500 | 2531.67 | 1.53% | 101.27% |
5000 | 5051.67 | 1.13% | 101.03% |
10000 | 9870.00 | 2.42% | 98.70% |
理论浓度(ng/L) | 检测平均值(ng/L) | RSD | 回收率 |
0 | 0 | — | — |
0.01375 | 0.01445 | 25.03% | 105.11% |
0.0275 | 0.03 | 6.26% | 104.12% |
0.055 | 0.06 | 7.96% | 101.61% |
0.11 | 0.11 | 4.05% | 103.03% |
0.22 | 0.21 | 2.94% | 95.68% |
0.441 | 0.42 | 4.41% | 94.63% |
0.881 | 0.84 | 2.72% | 95.89% |
1.56 | 1.59 | 1.68% | 101.71% |
3.13 | 3.23 | 1.30% | 103.09% |
6.25 | 6.48 | 1.68% | 103.60% |
12.5 | 12.78 | 1.67% | 102.27% |
25 | 25.08 | 1.52% | 100.33% |
50 | 50.28 | 1.51% | 100.57% |
100 | 99.07 | 2.47% | 99.07% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710262704.XA CN107064400B (zh) | 2017-04-20 | 2017-04-20 | 同时检测血清中五种类固醇激素的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710262704.XA CN107064400B (zh) | 2017-04-20 | 2017-04-20 | 同时检测血清中五种类固醇激素的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107064400A true CN107064400A (zh) | 2017-08-18 |
CN107064400B CN107064400B (zh) | 2018-09-21 |
Family
ID=59600357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710262704.XA Active CN107064400B (zh) | 2017-04-20 | 2017-04-20 | 同时检测血清中五种类固醇激素的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107064400B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110187043A (zh) * | 2019-04-25 | 2019-08-30 | 中南民族大学 | 一种同时检测血清中13种甾体激素的方法 |
CN110243977A (zh) * | 2019-07-19 | 2019-09-17 | 广州博厚健康科技有限公司 | 检测血清中四种孕激素的方法 |
CN110824091A (zh) * | 2019-12-17 | 2020-02-21 | 杭州度安医学检验实验室有限公司 | 一种类固醇激素检测方法 |
CN111103383A (zh) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | 一种液质联用同时测定人血浆中内源性皮质醇、皮质酯酮、雄烯二酮、睾酮浓度的方法 |
CN111175419A (zh) * | 2020-03-02 | 2020-05-19 | 山东英盛生物技术有限公司 | 一种同时检测血液样品中多种类固醇激素的方法及试剂盒 |
CN111398447A (zh) * | 2020-03-12 | 2020-07-10 | 南京品生医学检验实验室有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的试剂盒 |
CN111487328A (zh) * | 2019-01-27 | 2020-08-04 | 上海歌特维生物科技集团有限公司 | 一种用质谱法检测人体中多种痕量激素的方法 |
CN112964809A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 |
CN112964815A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 生物体液多种类固醇激素的检测方法 |
CN113544514A (zh) * | 2018-12-21 | 2021-10-22 | Dh科技发展私人贸易有限公司 | 使用lc-msms测量睾酮的方法 |
CN114088859A (zh) * | 2022-01-19 | 2022-02-25 | 北京金域医学检验实验室有限公司 | 一种分离多组同分异构体并检测29种类固醇激素的方法 |
CN114778737A (zh) * | 2022-04-27 | 2022-07-22 | 天津国科医工科技发展有限公司 | 可缩短时间的液相色谱检测样品前处理方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130228680A1 (en) * | 2008-10-06 | 2013-09-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydrotestosterone by mass spectrometry |
US20150125877A1 (en) * | 2013-09-04 | 2015-05-07 | Sten Ohlson | Weak Affinity Chromatography |
CN104807921A (zh) * | 2015-05-21 | 2015-07-29 | 上海迪安医学检验所有限公司 | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 |
WO2016191738A1 (en) * | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device |
CN106526026A (zh) * | 2016-11-10 | 2017-03-22 | 广州博厚医疗技术有限公司 | 血清中25‑羟基维生素d的检测方法 |
CN106568852A (zh) * | 2016-10-10 | 2017-04-19 | 南京医科大学 | 血清中与特发性男性不育相关的类固醇激素标志物及其检测方法和应用 |
-
2017
- 2017-04-20 CN CN201710262704.XA patent/CN107064400B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130228680A1 (en) * | 2008-10-06 | 2013-09-05 | Quest Diagnostics Investments Incorporated | Methods for detecting dihydrotestosterone by mass spectrometry |
US20150125877A1 (en) * | 2013-09-04 | 2015-05-07 | Sten Ohlson | Weak Affinity Chromatography |
CN104807921A (zh) * | 2015-05-21 | 2015-07-29 | 上海迪安医学检验所有限公司 | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 |
WO2016191738A1 (en) * | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device |
CN106568852A (zh) * | 2016-10-10 | 2017-04-19 | 南京医科大学 | 血清中与特发性男性不育相关的类固醇激素标志物及其检测方法和应用 |
CN106526026A (zh) * | 2016-11-10 | 2017-03-22 | 广州博厚医疗技术有限公司 | 血清中25‑羟基维生素d的检测方法 |
Non-Patent Citations (4)
Title |
---|
DAVID TAYLOR ET AL.: "Discrimination of adrenocortical carcinoma from other adrenal lesions: use of a new 13 steroid serum panel based on LC–MS/MS", 《ENDOCRINE ABSTRACTS》 * |
PAAL METHLIE ET AL.: "Multisteroid LC–MS/MS assay for glucocorticoids and androgens and its application in Addison’s disease", 《ENDOCRINE CONNECTIONS》 * |
TOSHIKAZU MINOHATA ET AL.: "《Shimadzu Corporation,www.shimadzu.com/an/》", 31 May 2016 * |
石先哲 等: "在线微柱富集纳升液相色谱-串联质谱法测定大鼠脑组织中类固醇激素", 《分析化学研究报告》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113544514A (zh) * | 2018-12-21 | 2021-10-22 | Dh科技发展私人贸易有限公司 | 使用lc-msms测量睾酮的方法 |
CN111487328A (zh) * | 2019-01-27 | 2020-08-04 | 上海歌特维生物科技集团有限公司 | 一种用质谱法检测人体中多种痕量激素的方法 |
CN110187043A (zh) * | 2019-04-25 | 2019-08-30 | 中南民族大学 | 一种同时检测血清中13种甾体激素的方法 |
CN110243977A (zh) * | 2019-07-19 | 2019-09-17 | 广州博厚健康科技有限公司 | 检测血清中四种孕激素的方法 |
CN110243977B (zh) * | 2019-07-19 | 2022-04-01 | 广州博厚健康科技有限公司 | 检测血清中四种孕激素的方法 |
CN112964809A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 |
CN112964815A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 生物体液多种类固醇激素的检测方法 |
CN110824091A (zh) * | 2019-12-17 | 2020-02-21 | 杭州度安医学检验实验室有限公司 | 一种类固醇激素检测方法 |
CN111103383A (zh) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | 一种液质联用同时测定人血浆中内源性皮质醇、皮质酯酮、雄烯二酮、睾酮浓度的方法 |
CN111175419A (zh) * | 2020-03-02 | 2020-05-19 | 山东英盛生物技术有限公司 | 一种同时检测血液样品中多种类固醇激素的方法及试剂盒 |
CN111398447A (zh) * | 2020-03-12 | 2020-07-10 | 南京品生医学检验实验室有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的试剂盒 |
CN114088859A (zh) * | 2022-01-19 | 2022-02-25 | 北京金域医学检验实验室有限公司 | 一种分离多组同分异构体并检测29种类固醇激素的方法 |
CN114778737A (zh) * | 2022-04-27 | 2022-07-22 | 天津国科医工科技发展有限公司 | 可缩短时间的液相色谱检测样品前处理方法 |
CN114778737B (zh) * | 2022-04-27 | 2024-05-10 | 天津国科医疗科技发展有限公司 | 可缩短时间的液相色谱检测样品前处理方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107064400B (zh) | 2018-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107064400B (zh) | 同时检测血清中五种类固醇激素的方法 | |
CN106526026B (zh) | 血清中25-羟基维生素d的检测方法 | |
US20170328921A1 (en) | Methods for detecting hormones and other analytes | |
CN104807921B (zh) | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 | |
Gosetti et al. | Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review | |
CN104807920B (zh) | 一种试剂盒在利用高效液相色谱串联质谱技术检测血清中10种类固醇激素中的应用 | |
Keski-Rahkonen et al. | Fast and sensitive liquid chromatography–mass spectrometry assay for seven androgenic and progestagenic steroids in human serum | |
Ray et al. | Performance enhancement in the measurement of 5 endogenous steroids by LC–MS/MS combined with differential ion mobility spectrometry | |
Ye et al. | High-performance liquid chromatography–tandem mass spectrometry for the analysis of bile acid profiles in serum of women with intrahepatic cholestasis of pregnancy | |
CN104215716B (zh) | 一种检测人血清中总睾酮的方法 | |
Xia et al. | Quantitation of ursolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry and its pharmacokinetic study | |
US20110240842A1 (en) | Methods and Systems for the Quantitative Analysis of Biomarkers | |
Li et al. | Ultra performance liquid chromatography–tandem mass spectrometry for the determination of epirubicin in human plasma | |
Jourdil et al. | Ultra-fast cyclosporin A quantitation in whole blood by laser diode thermal desorption–tandem mass spectrometry; comparison with high performance liquid chromatography–tandem mass spectrometry | |
Kuhn et al. | Sample cleanup-free determination of mycophenolic acid and its glucuronide in serum and plasma using the novel technology of ultra-performance liquid chromatography–electrospray ionization tandem mass spectrometry | |
US11536733B2 (en) | Methods and systems for the detection of 11-oxo androgens by LC-MS/MS | |
CN110243977A (zh) | 检测血清中四种孕激素的方法 | |
CN114200038A (zh) | 液相色谱-质谱联用检测藿香正气口服液中化合物含量的方法 | |
CN108693280A (zh) | 通过uplc-ms/ms定量测定生物样品中德谷胰岛素含量的方法 | |
Mathurin et al. | Gas chromatography–combustion–isotope ratio mass spectrometry analysis of 19-norsteroids: application to the detection of a nandrolone metabolite in urine | |
Vicente et al. | Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry | |
CN116519850B (zh) | 一种快速检测血清样本中16种激素浓度的方法 | |
Maddela et al. | A novel and Rapid LC–MS/MS assay for the Determination of Mycophenolate and Mycophenolic Acid in Human Plasma | |
Yan et al. | Sensitive and reliable multianalyte quantitation of herbal medicine in rat plasma using dynamic triggered multiple reaction monitoring | |
Abuín et al. | Analysis of thyreostatic drugs in thyroid samples by ultra-performance liquid chromatography tandem mass spectrometry detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 510663 G7 Block 302, 31 Kefeng Road, Guangzhou High-tech Industrial Development Zone, Guangdong Province Patentee after: Guangzhou Bohou Health Technology Co.,Ltd. Address before: 510663 Room 701, Building G1, 31 Kefeng Road, Science City, Guangzhou High-tech Industrial Development Zone, Guangzhou, Guangdong Province Patentee before: BIOHOP HEALTH TECHNOLOGIES CO.,LTD. |
|
CP03 | Change of name, title or address | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for simultaneously detecting five kinds of steroid hormones in serum Effective date of registration: 20190625 Granted publication date: 20180921 Pledgee: China Co. truction Bank Corp Guangzhou economic and Technological Development Zone sub branch Pledgor: Guangzhou Bohou Health Technology Co.,Ltd. Registration number: 2019440000235 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230403 Granted publication date: 20180921 Pledgee: China Co. truction Bank Corp Guangzhou economic and Technological Development Zone sub branch Pledgor: Guangzhou Bohou Health Technology Co.,Ltd. Registration number: 2019440000235 |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 510000 Room 501, building G7, 31 Kefeng Road, Huangpu District, Guangzhou City, Guangdong Province Patentee after: BIOHOP HEALTH TECHNOLOGIES CO.,LTD. Address before: 510663 G7 Block 302, 31 Kefeng Road, Guangzhou High-tech Industrial Development Zone, Guangdong Province Patentee before: Guangzhou Bohou Health Technology Co.,Ltd. |